Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8

Journal of Infectious Diseases

Volumn 205, Issue 7, 2012, Pages 1121-1130

  Tokumoto, Yoshio ^a   Hiasa, Yoichi ^a   Uesugi, Kazuhiro ^a   Watanabe, Takao ^a   Mashiba, Toshie ^a   Abe, Masanori ^a   Kumagi, Teru ^a   Ikeda, Yoshio ^a   Matsuura, Bunzo ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERLEUKIN 8; MESSENGER RNA; PEGINTERFERON ALPHA; PROTEIN KINASE R; RIBAVIRIN; TRANSCRIPTION FACTOR AP 1;

ANTIVIRAL ACTIVITY; ARTICLE; AUTOCRINE EFFECT; CELL STRAIN HEPG2; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MYXOVIRUS RESISTANCE A GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; VIRUS GENE; VIRUS REPLICATION;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERLEUKIN-8; MALE; MIDDLE AGED; RIBAVIRIN; T-LYMPHOCYTES; TRANSCRIPTIONAL ACTIVATION; VIRUS REPLICATION;

EID: 84863251369     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis025     Document Type: Article

References (36)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20:1-16. (Pubitemid 30421405)
2. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-22.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65. (Pubitemid 32913521)
4. Sidwell RW, Huffman JH, Khare GP, Allen LB,Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4- triazole-3-carboxamide. Science 1972; 177:705-6.
5. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983; 308:1443-7. (Pubitemid 13103444)
6. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001; 276:46094-8.
7. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000; 118:346-55. (Pubitemid 30067508)
8. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000; 44:859-66. (Pubitemid 30165261)
9. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003; 310:333-42. (Pubitemid 37492916)
10. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, Chung RT. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 2002; 76:8505-17. (Pubitemid 34864045)
11. Asahina Y, Izumi N, Enomoto N, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43:623-9. (Pubitemid 41253229)
12. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-8. (Pubitemid 26373872)
13. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897-903.
14. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-45. (Pubitemid 41191669)
15. Zhou A, Paranjape JM, Der SD, Williams BR, Silverman RH. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 1999; 258:435-40. (Pubitemid 29390253)
16. Tokumoto Y, Hiasa Y, Horiike N, et al. Hepatitis C virus expression and interferon antiviral action is dependent on PKR expression. J Med Virol 2007; 79:1120-7. (Pubitemid 47015411)
17. Hiasa Y, Blackard JT, Lin W, et al. Cell-based models of sustained, interferon-sensitive hepatitis C virus genotype 1 replication. J Virol Methods 2006; 132:195-203. (Pubitemid 43220180)
18. Hiasa Y, Kuzuhara H, Tokumoto Y, et al. Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta. Hepatology 2008; 48: 59-69. (Pubitemid 351975531)
19. Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci U S A 1997; 94:8738-43. (Pubitemid 27335109)
20. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-6. (Pubitemid 41021213)
21. Zhao D, Keates AC, Kuhnt-Moore S, MoyerMP, Kelly CP, Pothoulakis C. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001; 276:44464-71.
22. Wu GD, Lai EJ, Huang N, Wen X. Oct-1 and CCAAT/enhancer-binding protein (C/EBP) bind to overlapping elements within the interleukin- 8 promoter. The role of Oct-1 as a transcriptional repressor. J Biol Chem 1997; 272:2396-403. (Pubitemid 27058528)
23. Sumpter R Jr, Loo YM, Foy E, et al. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79:2689-99. (Pubitemid 40270547)
24. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010; 139:154-62.
25. Lalle E, Calcaterra S, Horejsh D, et al. Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents 2008; 22:153-60.
26. Abe H, Hayes CN, Ochi H, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54:1094-101.
27. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32-41.
28. Vivithanaporn P, Maingat F, Lin LT, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 2010; 5:e12856.
29. Li K, Chen Z, Kato N, Gale M Jr, Lemon SM. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J Biol Chem 2005; 280:16739-47. (Pubitemid 41389131)
30. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-17.
31. Van Damme J, Decock B, Conings R, Lenaerts JP, Opdenakker G, Billiau A. The chemotactic activity for granulocytes produced by virally infected fibroblasts is identical to monocyte-derived interleukin 8. Eur J Immunol 1989; 19:1189-94. (Pubitemid 19196894)
32. Koo BC, McPoland P, Wagoner JP, Kane OJ, Lohmann V, Polyak SJ. Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol 2006; 80:7885-93. (Pubitemid 44182289)
33. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75:6095-106. (Pubitemid 32553140)
34. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin- 8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001; 75:6209-11. (Pubitemid 32553153)
35. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000; 72:391-8.
36. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997; 9:240-6. (Pubitemid 27135992)